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Background and Aims 
Success in delivering value-based healthcare involves measuring outcomes that matter most 
to patients. Our aim was to develop a minimum Standard Set of patient-centred outcome 
measures for inflammatory bowel disease (IBD), for use in different healthcare settings. 
 
Methods 
An international working group (n=25) representing patients, patient associations, 
gastroenterologists, surgeons, specialist nurses, IBD registries and patient-reported outcome 
measure (PROM) methodologists participated in a series of teleconferences incorporating a 
modified Delphi process. Systematic review of existing literature, registry data, patient focus 
groups and open review periods were used to reach consensus on a minimum set of 
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standard outcome measures and risk adjustment variables. Similar methodology has been 
used in 21 other disease areas (www.ichom.org). 
 
Results 
A minimum Standard Set of outcomes was developed for patients (aged >16) with IBD. 
Outcome domains included survival and disease control (survival, disease activity/remission, 
colorectal cancer, anaemia), disutility of care (treatment-related complications), healthcare 
utilisation (IBD-related admissions, emergency room visits) and patient-reported outcomes 
(including quality of life, nutritional status and impact of fistulae) measured at baseline and at 
6 or 12 month intervals. A single PROM (IBD-Control questionnaire) was recommended in 
the Standard Set and minimum risk adjustment data collected at baseline and annually were 
included: demographics, basic clinical information and treatment factors. 
 
Conclusions 
A Standard Set of outcome measures for IBD has been developed based on evidence, 
patient input and specialist consensus. It provides an international template for meaningful, 
comparable and easy-to-interpret measures as a step towards achieving value-based 
healthcare in IBD. (248 words) 
 
Keywords  
Inflammatory Bowel Disease, Patient Reported Outcomes, Quality Improvement 
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INTRODUCTION 
A paradigm change is happening in healthcare. Many healthcare organisations are 
embracing value-based healthcare,1-4 an approach that aims to achieve the best possible 
health outcomes for the lowest cost.5, 6 According to the framework presented by Porter et 
al,7 the key to determining “value” is measuring outcomes that matter most to patients. When 
providers are asked to report outcomes, performance improves1 even when those outcomes 
are not patient-defined. Outcome measurement (in contrast to more familiar measures of the 
care-delivery process5, 6) has the potential to direct resources towards strategies with the 
highest value, which is particularly relevant for chronic diseases that are major drivers of 
healthcare costs.8 For complex conditions such as inflammatory bowel disease (IBD), the 
potential gain from a value-driven healthcare strategy could be even greater than conditions 
with defined interventions, such as cataract surgery.9 
Crohn’s disease (CD) and ulcerative colitis (UC), collectively known as IBD, 
disproportionately affect young adults in their educationally and economically productive 
years, leading to reduced quality of life, social functioning and productivity,10-13 often 
requiring lifelong drug treatment or major surgery.14, 15 This accounts for high costs to the 
healthcare system and society,10, 16, 17 with annual direct healthcare costs in Europe alone 
estimated at 4.6 – 5.6 billion Euros, and a global rise in burden, particularly in East Asia.12, 18-
20 Despite the potential impact on the individual, no patient-reported outcome measures 
(PROMs) are used in routine practice, so patient-reported outcomes (PROs), other than 
disease-related symptoms, are rarely captured. Furthermore, there remains widespread 
variation in clinical practice and quality of care provided to patients with IBD.21-23 With the 
exception of collaborations such as the ImproveCareNow network,24-26 current IBD registries 
track different outcomes or similar outcomes with different definitions, making meaningful 
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comparisons between populations difficult.27 Similarly, no ‘core outcome sets’ are currently 
available for IBD clinical trials to date, limiting the ability for direct comparison or combining 
of results.28 
To align outcome measurement in IBD as a step towards value-driven care, the Oxford 
Academic Health Science Network collaborated with International Consortium for Health 
Outcomes Measurement (ICHOM) to form an IBD Working Group of clinical and outcome 
specialists, patients and their associations (Crohn’s & Colitis Foundation of America, CCFA; 
Crohn’s & Colitis UK, CCUK; and Association François Aupetit, AFA) from 12 countries. 
ICHOM is a non-profit organisation founded in 2012 by Michael Porter of Harvard Business 
School, the Boston Consulting Group and the Karolinska Institutet (www.ichom.org), that 
aims to drive quality improvement and reduce variation in standards between healthcare 
providers through outcome measurement. This has resulted (as of 2017) in 21 Standard 
Sets of outcomes for different medical conditions that are being implemented in practice.29-35. 
The advantage of this collective effort is that all use standardised methodology; 
consequently each condition becomes part of a wider whole for introducing outcome 
measurement into routine practice, facilitating implementation when different disease areas 
can learn from others.  
Our goal was to develop a minimum Standard Set of patient-centred outcomes for IBD to 
provide a common language for outcomes that can be tracked systematically. 
 
MATERIALS AND METHODS 
Context and overview 
The Standard Set for patients with IBD (age ≥16y) aims to provide a template with 
meaningful, comparable and easy-to-interpret measures that can be implemented in any 
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healthcare setting to track and compare outcomes. It represents a ‘minimum’ standard to 
cover the cycle of care for both CD and UC and tracks health status (Figure 15), while not 
precluding collection of additional measures. 
Selection principles for outcomes were:  
(1) feasible to capture in routine clinical practice;  
(2) the end results of care, not the process of care;  
(3) important to patients with IBD; and  
(4) responsive to change.  
Four domains (Survival and Disease Control; Symptoms, Function, and Quality of Life; 
Disutility of Care; and Healthcare Utilisation) were pre-specified, but not the number of 
measures. For PROMs, considerations included domain coverage and psychometric 
properties.36, 37 In the selection of the PROM tool, we aimed to capture health status and 
impact on quality of life beyond specific disease-related symptoms using a validated 
instrument applicable to both CD and UC. Time points for data collection were determined 
by considering these principles and the burden of data capture on the patient or provider. 
Case-mix variables for risk adjustment were selected by: (1) the relevance (strength of 
causal linkage between the characteristic and the outcome); (2) independency; (3) 
practicality; and (4) comparability at a global level. 
 
The Project Team and Working Group 
The Project Team comprised a Chair (ST), an ICHOM Project Leader (CR), and a Research 
Fellow (AK) responsible for co-ordinating a series of teleconferences and consensus 
process. Material for discussion at each call was jointly prepared by the Project Leader and 
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the Research Fellow who reviewed available registry data and evidence from scientific 
literature. The Project Team invited patient associations to recommend patients or 
representatives and identified internationally recognised specialists. In accordance with 
standard ICHOM criteria, final selection of Working Group members considered 1) expertise, 
as evidenced by publications on patient outcomes, invitation to speak at international 
conferences, or national-level leader status, 2) representation of different geographical areas 
and areas of expertise, 3) availability in terms of being able to participate in discussions 
during teleconferences, and 4) having no conflict of interest that could compromise the 
neutrality of the Standard Set. The resulting Working Group (n=25, see author list) 
represented seven specialties or interest groups (patients, gastroenterologists, surgeons, 
specialist nurses, IBD registries, PROM methodology specialists and representatives of 
large patient organisations) from 12 countries (Australia, Belgium, Brazil, Canada, China, 
France, Germany, India, Netherlands, South Korea, UK and USA). 
 
Consensus Process 
A systematic literature review to identify IBD-related outcomes, relevant definitions and 
measurement tools of electronic databases (Medline, EMBASE, PsychInfo, Cumulative 
Index to Nursing and Allied Health Literature, Allied and Complementary Medicine, 
University of Oxford PROM bibliography database – to 2005, the Cochrane Library) was 
undertaken. The search strategy was deliberately chosen to capture all studies that reported 
on any clinical or patient-reported outcomes (including instruments used to measure them) 
for IBD, without restricting the search to specific domains or time frame, although it was 
limited to randomised controlled trials, reviews, and meta-analyses published in English (see 
Supplementary Material 1, available as Supplementary Data at ECCO-JCC online).This was 
supplemented by manual searching of references from key journals that included published 
IBD guidelines and reviews of IBD-related outcomes. The group convened 8 teleconferences 
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and 7 online surveys incorporating a modified two-round Delphi process38 to reach 
consensus based on evidence and specialist opinion between October 2015 and July 2016. 
Before each teleconference, the Project Team circulated an agenda, list of key proposals 
and relevant evidence from the literature for review where relevant outcomes and metrics 
were organised into summary tables using a defined hierarchy – these were then used to 
generate the discussions with all participants at each call contributing to key decisions.  
 
Each teleconference was followed by minutes and an online survey for feedback and voting 
(from all Working Group members including non-participants of the call). Key decision areas 
included: (1) the scope to be covered by the Standard Set (Calls 1 and 2, 1 survey); (2) 
items to be included in the Standard outcome set including definition, response options, data 
source, and timing of collection (Calls 2-5, 3 surveys); and (3) case-mix factors required for 
risk adjustment including definition, response options, data source, and timing of collection 
(Calls 5-8, 3 surveys). ‘Consensus’ was predefined as greater than 70% of the voting 
Working Group members rating the item as very important (score of 7-9 on a 9-point Likert 
scale) in either voting round. The Project Team was excluded from voting, giving a maximum 
of 22 possible votes for each item. Results as percentage agreement were then made 
available to all Working Group members. Any items where consensus was not reached but 
ranked 7-9 by at least 50-70% of respondents were further discussed, followed by a second 
survey. Items ranked 7-9 by less than 50% of respondents were excluded from further 
surveys. Similarly, any newly introduced items, change in definition or timing of collection 
were subject to further surveys to reach consensus. All voted items were reviewed at the 
subsequent teleconference, whether voted in or out as per pre-defined consensus definition, 
to provide an additional opportunity for any of the Working Group members to challenge or 
confirm their inclusion. 
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A patient focus group including six IBD patients and two 1:1 patient interviews were 
conducted39 by CR after the Working Group launch, to obtain patients’ perspectives on 
outcomes that matter most to them, using a structured interview and open-ended questions. 
Participants, nominated by CCUK and Crohn’s & Colitis Australia, discussed which 
outcomes were of greatest importance to them. The focus groups represented a mix of 
patients with CD or UC who had received a variety of surgical and/or medical treatments 
with different healthcare utilisation experiences. Additional 1:1 interviews were undertaken 
for one man and one pregnant woman. Representatives of patient associations and other 
Working Group members shared their experience with other patient focus groups22, 40-42 
during teleconferences to confirm that the most important patient-reported outcome domains 
and patient concerns were represented in the Standard Set. 
 
The resulting Standard Set was approved unanimously by the Working Group before being 
subject to patient validation surveys and a period of open review by interested clinicians 
before finalisation. The patient validation surveys involved circulation of the Standard Set to 
geographically and culturally diverse group of patients with the aid of multiple patient 
organisations, including CCUK and Crohn’s & Colitis Australia as well as local patient groups 
invited by Working Group members from Brazil, India, and China (PK, RB, ZhR). The survey 
was translated into French, Hindi, Brazilian Portuguese, and simplified Chinese. It was 
completed by 318 patients representing a diverse age group and geographical location, with 
83% indicating that they felt that the current Standard Set captured the most important 
outcomes that matter or have mattered to them (see Supplementary Material 2, available as 
Supplementary Data at ECCO-JCC online). A web-based draft version of the Standard Set 
was made available to interested clinicians, ICHOM website registrants and other 
stakeholders for comment on the Standard Set before finalisation. 
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RESULTS 
Scope: Patients with Inflammatory Bowel Disease 
The agreed focus (75%, n=16/20) was all patients (age >16y) with IBD defined by 
International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) 
diagnosis codes K50 (CD), K51 (UC) and K52.3 (IBD-Undetermined [IBD-U]). Children (age 
<16y) were excluded because PROMs derived for adults were potentially inapplicable and 
the Montreal classification of IBD43 uses this threshold, recognising that transitional care for 
young people with IBD can begin as early as age 1444-46 Other non-infective causes of colitis 
in ICD-10 code K52 were excluded. 
 
Systematic Review of IBD-related Outcomes and Measures 
Using a defined hierarchy,5 outcomes and metrics were selected from 565 papers and 
abstracts for the Working Group, which was further informed by registry databases and input 
from patient focus groups. In the four domains, 239 preliminary outcome measures were 
identified, from which 14 measures and their instruments were selected (see Supplementary 
Material 3 and 4, available as Supplementary Data at ECCO-JCC online).  
 
The Standard Set: Outcome Domains and Measures  
Survival and Disease Control 
Four measures were selected (Figure 2). Although death attributable to IBD is infrequent, it 
is of overriding relevance to patients, highlighted by patient focus groups. Capturing overall 
survival allows the ultimate impact of care to be assessed. Recognising the limitations of 
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death registries and reporting in many countries, the Working Group voted (82%, n=14/17) 
to include both overall and IBD-specific survival. The Working Group recommends tracking 
survival each year. 
Control of disease activity and remission is one of the major goals of treatment. Defining 
remission, however, is not straightforward and no agreed tool currently exists to capture 
disease activity, which in itself can be defined in many ways. There is often discrepancy 
between the patient’s symptoms and their state of biological remission, so the Working 
Group considered these separately. The consensus (100%, n=17/17) was to use the 
Manitoba IBD index (MIBDI)47 (Table 2) for both UC and CD at baseline and 6-monthly 
intervals. The MIBDI is a single-item, patient-defined disease activity measure reported on a 
6-point Likert scale allowing a 6-month recall period. It has been validated against Harvey-
Bradshaw Index, Powell-Tuck Index, and the Inflammatory Bowel Disease Questionnaire 
(IBDQ).48 The Working Group decided (88%, n=16/18; 94%, n=17/18) that the clinician 
should separately report clinical remission and biological remission, and document how 
biological remission was determined (biochemical, endoscopic, imaging). 
Colorectal cancer, although infrequently complicating IBD,49 was important to patient focus 
groups. The Working Group agreed (94%, n=16/17), since treatment may alter this outcome. 
Annual tracking of a definitive diagnosis was recommended, and for affected patients, 
reporting whether colorectal dysplasia had previously been diagnosed, and whether they 
had been participating in colorectal cancer surveillance. Surveillance details were 
considered to be beyond the scope of minimum standards. 
Anaemia, defined by the World Health Organisation (WHO),50 was recommended (71%, 
n=12/17) as an independent marker of disease activity and potentially modifiable outcome, 
tracked at baseline and at 6-monthly intervals. 
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Healthcare Utilisation 
Two measures were selected (Figure 2). Unplanned admissions or Emergency Department 
visits concern patients with IBD, since they can imply suboptimal disease control, non-
specialist care, or increased use of ionising radiation (CT scans).22 To achieve a practical 
measure, the Working Group recommended (71%, n=12/17) recording the total number of 
emergency room visits every 12 months and all IBD-related admissions requiring at least an 
overnight stay, defined as planned or unplanned, and recording the total length of stay in 
days over a 12-month period. 
 
Disutility of Care 
Two measures were selected (Figure 2). Complications resulting from IBD-related treatment 
are a central concern for patients that informs their choices about management. Attribution 
to disease or therapy is contentious and determining severity is difficult. The Working Group 
recommended (76%, n=14/18) documenting a complication that occurred during or within 3 
months of any treatment (medical, endoscopic, radiological, or surgical), separately 
recording the outcome (further intervention, unplanned admission, or prolonged 
hospitalisation).  
Steroid dependency is a cause of morbidity in IBD, is a concern to patients and may reflect 
quality of care.51, 52 The Working Group recommended (82%, n=14/17) documenting any 
systemic steroid use within the previous 12 months and whether the duration exceeded 3 
months. 
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Symptoms, Function, and Quality of Life (Patient-Reported Outcomes 35) 
One tool was selected to cover five measures that matter to patients (change in bowel 
symptoms, pain & discomfort, normal activities, energy & fatigue, and depression & anxiety) 
(Figure 2). The tool recommended (100%, n=20/20) was the IBD-Control Questionnaire,42 
applied every 6 months. All IBD-specific PROMs were examined by specialists within the 
Working Group (RF, WvD) for their conceptual and measurement designs, domain coverage 
and psychometric properties using ISOQOL criteria (Table 3).36 Although the best 
established PROM in IBD is the Inflammatory Bowel Disease Questionnaire (IBDQ),48 it has 
failed to embed itself in clinical practice because of its length and need for a licence. The 
IBD-Control questionnaire42 captures disease control from the patient’s perspective using 
generic language and measuring themes with which all patients with IBD can identify. It can 
be administered in less than a minute and has shown strong validity against EQ-5D,53 UK-
IBDQ,54 Harvey-Bradshaw Index55 / Simple Clinical Colitis Activity Index,56 and Physician 
Global Assessment. For the purpose of the Standard Set, the Working Group selected 
Questions 1, 2, and 3 of the IBD Control Questionnaire to be included (Table 4) which 
adequately covered the five measures of interest.   
Nutritional status and impact of fistulae (for patients with CD) were considered separately. 
No simple, responsive measure for either could be identified. The Working Group 
recommended (100%, n=19/19) recording height and weight at baseline as a surrogate 
marker for nutritional status, from which the Body Mass Index (BMI) can be calculated, then 
the change in weight at 6 monthly intervals. For fistulae, a single question on presence or 
absence of a fistula (none, perianal, rectovaginal, enterocutaneous, or other) was added, to 
be completed at baseline and 6-monthly intervals. 
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Case-mix Variables for Risk Adjustment 
The Working Group defined a minimum set of patients’ baseline characteristics (Table 5) to 
enable comparisons of outcomes between centres, regions or countries to be placed in 
context. Selection had to be practical to capture in routine care, balancing the burden with 
the need for accurate comparisons. The categories of case-mix variables included: 
demographics (year and sex at birth, education level, smoking status), baseline clinical 
factors (Self-reported Comorbidity Questionnaire, SCQ,57 with specific inclusion of 
autoimmune conditions and previous infections with Human Immunodeficiency Virus, 
hepatitis B virus, or tuberculosis), baseline condition factors (diagnosis, date of diagnosis, 
disease phenotype using Montreal Classification,43 and presence of extra-intestinal 
manifestations categorised as eye, skin, joint, hepatobiliary or other), and treatment factors 
(current medication: no IBD drugs, steroids, biologics, immunomodulators, other; type of 
IBD-related surgery). Demographics and baseline clinical factors will be patient-reported, 
whilst baseline condition and treatment factors will be clinician-reported at baseline, and 
tracked annually as appropriate for smoking status, disease location/behaviour and 
treatment.  
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DISCUSSION 
A ‘minimum’ set of standardised outcome measures represents a common language that 
can be used across healthcare jurisdictions as a step towards value-driven care in IBD. 
Value-driven care relies on reporting and systematic tracking of patient-centred outcomes, 
allowing providers to compare meaningful outcomes for patients and to adopt strategies that 
achieve the best ‘value’ for participating stakeholders. This work represents a first step. The 
performance characteristics of the measures need evaluating in real world practice. If 
adopted and implemented, such an approach has the potential to reduce variations in 
practice and improve standards of care on a global scale. 
Existing studies show wide variations in the quality and delivery of care in IBD and suggest 
significant potential for improvement. National audit in the UK in 2006 led to the development 
of a set of IBD Standards that defined key performance indicators and recommendations for 
quality, patient-centred care.23 In the United States, a collaborative of paediatric IBD centres 
formed the ImproveCareNow network to develop an outcomes registry using a shared, 
prospective database between nearly 50 centres. Over the years, remission rates within the 
participating centres have increased from 55% to 75%, using physician’s global 
assessment.24 This highlights what can be achieved when the provision of care is driven by 
outcomes. 
The Standard Set presented here is the first coordinated international, multidisciplinary effort 
to reach a precisely defined core set of outcomes for all adult patients with IBD. The 
development process has followed reporting guidelines for core outcome sets.58 This is an 
advantage, because IBD becomes just one of many (21 diseases as of 2017, 
www.ichom.org) diseases subject to the same process. The final Standard Set (Figure 2) 
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tracks 14 outcome measures that encompass the full cycle of care for both CD and UC, as 
well as health status beyond completion of care. The selection process was guided by 
careful consideration of the hierarchy of outcome measures and pre-specified domains. 
Each of the selected outcome measures was subject to voting on definition, response 
options and data source in a formal consensus process. Practicality in terms of burden on 
the patient and/or the provider, and feasibility in a broad range of healthcare settings were 
additional considerations. 
Importantly, the Standard Set emphasises outcomes that matter most to patients. The US 
Food and Drugs Administration has advocated routine inclusion of PROs as co-primary 
endpoints in clinical trials.59 Although improving quality of life is a common secondary 
endpoint in clinical trials, it has been the primary endpoint in only one trial in IBD60 and is 
rarely captured in routine practice. Whilst the IBDQ has been widely used in trials, it has 
failed to embed itself in routine practice because of its length, and pragmatic reasons of cost 
and administrative burden. A shorter version,61 and other more recent variations of the IBDQ 
such as the UK version of the IBDQ54 and Crohn’s and Ulcerative Colitis Questionnaire62 
have similarly failed to gain popularity. The IBD-Control Questionnaire,42 unanimously 
recommended by the Working Group, is a PROM tool developed with the primary aim of 
supporting patient-centred care in practice. It captures the patient’s perspective on disease 
control using a simple set of generic items applicable to all patients with IBD. It is freely 
available without a licence and takes less than 60 seconds to complete, which gives it great 
potential in routine practice. Strong psychometric properties have led to its selection for the 
UK IBD registry although it is yet to be validated in other languages apart from Spanish. The 
Standard Set of outcomes defined here are designed for clinical practice and would only be 
adaptable to clinical trials once performance characteristics are defined by prospective 
measurement. 
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Parallel efforts to define PROMs in IBD have been driven by the CCFA within the United 
States whose 10 most highly rated process and outcome measures were published in 
2013.22 The current Working Group took advantage of this work by including key patient, 
association and clinical specialist representatives involved in the CCFA process. Similarly, 
the National Institutes of Health Patient-Reported Outcomes Measurement Information 
System metrics were developed for gastrointestinal symptoms in 2014.63 The development 
process and selected measures of both these initiatives reassuringly have much in common 
with ICHOM, but challenges remain with standardisation of these measures. Strengths of the 
ICHOM Standard Set include international representation of patients and clinicians’ 
perspectives (including low income countries), precise definitions of outcome measures and 
data sources for implementation, as well as recommended timelines for data collection. A 
minimum set of baseline characteristics (case-mix variables) has been determined to allow 
meaningful comparisons between populations via risk adjustment. The IBD Standard Set 
was further subject to patient validation surveys in several languages for global 
implementation and open review for comment by interested clinicians before finalisation. 
Standard Sets remain open to modification by international agreement.    
Nevertheless, the Standard Set has limitations. Patient numbers involved in focus groups 
and face to face interviews were few: however, unlike evidence-based science, the 
methodology of qualitative research and quality improvement depends not on numbers but 
the extent to which concepts reflect the opinions of representative groups. There is no 
standard for determining an adequate group size64 and work in other fields has considered 
groups of 5-10 patients to be optimal.39, 65 Symptom domains of importance and concerns 
identified by our focus groups reflected those of earlier work by patient associations and 
others.23, 40, 41, 66-68 Patient representatives on the Working Group (MD, JM, HT, AW) present 
for the discussions and final decisions represented large patient organisations (CCFA, 
CCUK, and AFA). More patients, groups and a wider validation survey might have been 
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involved, but a balance had to be struck between resources and delivery within a 12 month 
timeframe.       
Despite the Working Group’s best efforts to develop consensus definitions that were 
unambiguous, cultural characteristics and infrastructural differences will inevitably influence 
local data. For some measures, this meant that a broad definition had to be adopted. For 
example, although readmission and unexpected admission were identified as important 
outcomes for the domain Healthcare Utilisation, the Working Group recognised the variation 
in thresholds for admission that exists between healthcare providers. It therefore chose to 
measure total length of stay and separately to track ED visits. The Standard Set also 
includes outcome measures that rely on pre-existing registry or administrative data. This is 
relevant for the Survival domain. Inaccurate or inconsistent information with respect to cause 
of death is well-recognised. However, death is a central concern to patients, so could not 
reasonably be excluded as an outcome. The Working Group chose to include “unknown” as 
a response option for cause of death. Furthermore, not all outcome measures had practical 
definitions or validated tools available. This was the case for nutrition. Existing tools such as 
the Malnutrition Universal Screening Tool69 act as a screening tool for referral (process 
measure) rather than monitoring. Tools requiring anthropometrics or incorporating 
biochemical measures were considered impractical. The Working Group chose to measure 
height and weight at baseline for BMI calculation and then change in weight as a surrogate 
marker of nutritional status and an outcome of care, because this is a universally-available, 
objective measure in low income countries where access to more costly assessments may 
be difficult. We used a modified two round Delphi process to reach consensus on each of the 
selected outcome measures and case-mix variables including how and when these should 
be captured. The level of consensus deemed necessary in the Delphi process remains 
ambiguous in the literature, and there are no agreed norms for size of consensus, with 
practice varying from basic majority to more stringent proportions. The level of agreement 
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used in our work was pragmatic, based on other successfully conducted international 
consensus processes for outcomes, including those used by ICHOM in other published 
Standard Sets. Notably, the Core Outcome Measures in Effectiveness Trials initiative used 
this cutoff.70 The minimum denominator for all votes was 17, representing 77-81% of the 
Working Group members (excluding the Project Team). It should be noted that whilst 
numbers formally participating in any given vote varied, all Working Group members were 
subsequently prompted for feedback and had the opportunity to confirm or challenge the 
results. The final Standard Set was approved unanimously by the Working Group. 
This international, multidisciplinary IBD Working Group has developed a minimum set of 
patient-centred outcomes, tools and PROMs for collection in patients with IBD. Data 
collection needs to be piloted and a standardised collection platform developed before data 
quality and outcomes can be compared in different settings. ICHOM is committed to 
facilitating broad adoption of this set and has made the full recommendations freely available 
on its website (www.ichom.org/medical-conditions/inflammatory-bowel-disease), along with a 
reference guide to assist with technical aspects of implementation. The near-term goal will 
be to implement the set and to use this as a proof of concept towards broader adoption or 
endorsement by payors and governments. A steering committee will oversee revisions to the 
Standard Set to reflect changes in data collection capacity, to clarify outcome or baseline 
characteristics definitions as needed and respond to improvements in outcome 
measurement tools. In this way, the international IBD community can move towards the 
ultimate goal of acquiring internationally comparable data on patient-centred outcomes and 
improve the value of care. 
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1 IBD-Control Questionnaire (Q1-3) 
2 The Manitoba IBD Index 
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Table 1. ICHOM Standard Set for Inflammatory Bowel Disease 
 
        
Patient 
Population 
Measure Supporting 
Information 
Timing Suggested 
Data Sources 
Symptoms, Function, and Quality of 
Life       
All patients 
Change in bowel 
symptoms 
Tracked via the IBD-
Control Baseline 
and 6-
monthly 
Patient-
reported 
Missing planned 
activities 
Night symptoms 
Pain or discomfort 
Energy and fatigue 
Feel anxious or 
depressed 
Overall control 
over IBD 
Weight 
N/A All patients with 
Crohn's Disease 
Fistula symptoms 
Disutility of Care         
All patients 
Steroid use 
Use of any systemic 
steroids within the 
previous 12 months 
Baseline 
and annual 
follow-up 
Clinician-
reported 
Occurrence and Including whether a 
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impact of 
complication from 
an IBD intervention 
complication occurred 
and the outcome of 
the complication 
Healthcare Utilisation       
All patients 
Time spent in 
hospital 
Including all IBD-
related admissions 
requiring an overnight 
stay and emergency 
department visits 
Baseline 
and annual 
follow-up 
Clinician-
reported 
Survival and Disease Control       
All patients 
Presence of 
anaemia 
Using WHO 
definitions 
Baseline 
and 6-
monthly 
Clinician-
reported 
Disease activity 
and remission 
Tracked via the 
Manitoba IBD Index 
and additional 
clinician report 
Patient and 
Clinician-
reported 
Colorectal cancer 
Diagnosis of 
colorectal cancer and 
preceding colorectal 
dysplasia 
Baseline 
and annual 
follow-up 
Clinician-
reported Overall survival Date of death 
Cause of death 
Death attributable to 
IBD or to an 
intervention for IBD 
     
 
Downloaded from https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjx161/4694039
by University of Liverpool user
on 18 December 2017
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjx161 
 
 
 
 
Table 2. The Manitoba IBD Index47 
 In the last 6 months, my disease has been 
 0 = Constantly active giving me symptoms every day 
1 = Often active, giving me symptoms most days 
2 = Sometimes active, giving me symptoms on some days (for instance 1-2 
days/week) 
3 = Occasionally active, giving me symptoms 1-2 days/month 
4 = Rarely active, giving me symptoms on a few days in the past 6 months 
5 = I was well in the past 6 months, what I consider a remission or absence of 
symptoms 
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Table 3. Domain coverage and psychometric properties of IBD specific PROMs 
 
Domain Coverage by IBD specific PROMs           
Outcome Domains* IBDQ SIBDQ IBDQ-9 UK-IBDQ 
CUCQ-
32 CUCQ-8 
IBD-
Control RFIPC IBD-DI 
Overall change in symptom status Partially No Partially No No No Yes No No 
Abdominal pain / discomfort Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Bowel habit Yes No Yes Yes Yes No Indirectly No Yes 
Rectal bleeding Yes No No Yes Yes No Indirectly No Yes 
Tenesmus Yes Yes No Yes Yes No Indirectly No No 
Night time bowel movement / leakage Indirectly No No No Yes Yes Yes No Indirectly 
Faecal incontinence Yes No No Yes Yes No Indirectly Yes No 
Perianal fistula / discharge / pain No No No No No No Indirectly No No 
Unintentional weight change Yes Yes No No No No No No No 
Health related QoL Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Fatigue and energy Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Emotional health Yes Yes Yes Yes Yes Yes Yes Yes Yes 
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Limitations to usual ADL No No No Yes Yes No Indirectly No Yes 
Work / education productivity Yes No No Yes Yes No Yes Partially Yes 
          *Outcomes preliminarily selected by Working Group for inclusion within the Symptoms, Function, and Quality of 
Life domain 
   
          
 
Psychometric Properties by IBD specific 
PROMs 
          
Psychometric Properties IBDQ SIBDQ IBDQ-9 UK-IBDQ 
CUCQ-
32 CUCQ-8 
IBD 
Control RFIPC IBD-DI 
Test-retest Reliability 
(= reproducibility) 
High High High High High High High High Med 
Reliability -  
Internal Consistency 
Med Med Med Med High High High High High 
Content Validity High High High High High High High High High 
Construct Validity Med Med Med Med High High High High High 
Responsiveness 
(Ability to detect change) 
Med Low Low Med Unknown Unknown High Low Unknown 
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Table 4. The IBD Control Questionnaire42 (Questions 1-3) 
           1. Do you believe that: 
        
 
a. Your IBD has been well controlled in the past 2
weeks? 
 
Yes/No/Not sure 
 
 
b. Your current treatment is useful in controlling your 
IBD? 
    
           2. Over the past 2 weeks, have your bowel symptoms been getting 
worse, Better/No change/Worse 
    getting better or not 
changed? 
       
           3. In the past 2 weeks, did you: 
       
 
a. Miss any planned activities because of IBD? 
  
Yes/No/Not sure 
 
 
  (e.g. attending school/college, going to work or a social event) 
   
 
b. Wake up at night because of symptoms of 
IBD? 
  
Yes/No/Not sure 
 
 
c. Suffer from significant pain or discomfort? 
  
Yes/No/Not sure 
 
 
d. Often feel lacking in energy (fatigued) 
  
Yes/No/Not sure 
 
 
  (by 'often' we mean more than half of the 
time) 
     
 
e. Feel anxious or depressed because of your IBD? 
 
Yes/No/Not sure 
 
 
f. Think you needed a change to your 
treatment? 
  
Yes/No/Not sure 
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Table 5. ICHOM Standard Set for Inflammatory Bowel Disease: Case-Mix and Treatment 
Variables 
     Patient 
Population 
Measure Supporting 
Information 
Timing Suggested 
Data Sources 
Demographics         
All patients 
Year of birth 
N/A 
Baseline 
Patient-
reported 
Male or female 
Education level 
Highest level of 
schooling completed 
using the International 
Standard Classification 
of Education 
Smoking status 
(of cigarettes, cigars or 
tobacco) 
Baseline and 
annual follow-
up 
Patient height 
To calculate BMI Baseline 
Patient weight 
Baseline Clinical Factors       
All patients 
Comorbidities 
including 
autoimmune 
N/A 
Baseline and 
annual follow-
up 
Patient-
reported 
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conditions 
Previous infection HIV, HBV or TB 
Baseline Condition Factors       
All patients 
Diagnosis 
Crohn's disease, 
ulcerative colitis, 
indeterminate IBD or 
colitis unclassified Baseline 
Clinician-
reported 
Date of diagnosis N/A 
Disease phenotype 
Tracked via Montreal 
Classification 
Presence of extra-
intestinal 
manifestations 
Eye, skin, joint, 
hepatobiliary or other 
Baseline and 
annual follow-
up 
Treatment 
Factors         
Surgical patients 
Type of IBD-related 
surgery 
Including method of 
surgical procedure, date 
of surgery, and type of 
colectomy Baseline and 
annual follow-
up 
Clinician-
reported 
Medical patients Current medication 
N/A 
Patients 
diagnosed with 
colorectal cancer 
Participation in a 
colorectal cancer 
surveillance 
programme 
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Figure 1. 
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Figure 2. 
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